Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Brian P McVeigh
AddedMar 31, 2024
UpdatedMay 31, 2026
Brian P McVeigh

Brian P McVeigh

Board Member, Genisphere

CrunchbaseLinkedIn

Brian P McVeigh's Career

Genisphere
Genisphere

Hatfield, PA, US

Board Member· Board
Code Biotherapeutics
Code Biotherapeutics

Hatfield, PA, US

Board Member· Board
KBP Biosciences
KBP Biosciences

Princeton, NJ, US

Co-Founder

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Brian P McVeigh's Career

Genisphere
Genisphere
Series A$6M91997Hatfield, PA, US
Board Member· Board

Leadership at Genisphere

Tom BlissTom BlissCEO
James KadushinJames KadushinFounder
Alan L. RubinoAlan L. RubinoBoard Member

Similar to Genisphere

NanotransferNanotransferSunnyvale, CA, USDrug Deliveryest. 2021NanotransferSunnyvale, CA, US · est. 2021

Nanotransfer develops versatile, safe, and cost-effective nanoparticle delivery systems for gene therapies, enhancing cellular internalization and specificity.

Pre-Seed · $200k4
Nanoscope TechnologiesNanoscope TechnologiesBedford, TX, USDiagnostics, Therapeuticsest. 2009Nanoscope TechnologiesBedford, TX, US · est. 2009

Nanoscope Technologies: Innovating scientific and biomedical solutions since 2009.

Series A · $4M18
CrystalplexCrystalplexPittsburgh, PA, USDiagnostics, Nanoparticlesest. 2004CrystalplexPittsburgh, PA, US · est. 2004

Crystalplex offers fluorescent nanoparticle tech for biomedical research and diagnostics.

Angel · $3.2M8
Advanced NanoTherapiesAdvanced NanoTherapiesLos Gatos, CA, USDrug Delivery, Nanoparticlesest. 2018Advanced NanoTherapiesLos Gatos, CA, US · est. 2018

Developing biodegradable nanoparticles to enhance drug uptake and retention for medical devices.

Series A · $16.5M12
Code Biotherapeutics
Code Biotherapeutics
Series A$85M472020Hatfield, PA, US
Board Member· Board

Leadership at Code Biotherapeutics

Dmitry KuzminDmitry KuzminBoard Member
Lori GettsLori GettsCo-Founder
Robert GettsRobert GettsCo-Founder
Diana BernsteinDiana BernsteinBoard Member
Joseph TruittJoseph TruittBoard Member

Similar to Code Biotherapeutics

Intergalactic TherapeuticsIntergalactic TherapeuticsCambridge, MA, USGene Therapyest. 2020Intergalactic TherapeuticsCambridge, MA, US · est. 2020

Intergalactic Therapeutics: Pioneering the future of non-viral gene therapy for patients.

Series A · $75M41
ReCode TherapeuticsReCode TherapeuticsMenlo Park, CA, USGenetic Therapiesest. 2015ReCode TherapeuticsMenlo Park, CA, US · est. 2015

ReCode Therapeutics: Developing targeted genetic therapies for life-limiting respiratory diseases.

Series B · $521.8M143
Encoded TherapeuticsEncoded TherapeuticsSouth San Francisco, CA, USPrecision Therapiesest. 2014Encoded TherapeuticsSouth San Francisco, CA, US · est. 2014

Encoded: Leveraging human genome power for effective precision therapies in genetic disorders.

Series D · $239.1M200
Apertura Gene TherapyApertura Gene TherapyNew York City, NY, USGene Therapyest. 2021Apertura Gene TherapyNew York City, NY, US · est. 2021

Apertura Gene Therapy: A biotech firm pioneering gene therapy for debilitating diseases.

Series A · $67M29
KBP Biosciences
KBP Biosciences
Series A$76M512007Princeton, NJ, US
Co-Founder

Leadership at KBP Biosciences

Fred YangFred YangCo-Founder
Johan SpoorJohan SpoorBoard Member
Zhenhua HuangZhenhua HuangBoard Member
Robert SegalRobert SegalCo-Founder

Similar to KBP Biosciences

Knopp BiosciencesKnopp BiosciencesPittsburgh, PA, USDrug Developmentest. 2004Knopp BiosciencesPittsburgh, PA, US · est. 2004

Knopp Biosciences, a US-based company, innovates breakthrough neurological disorder treatments, with a lead compound in development.

Series C · $164M10
Know BioKnow BioDurham, NC, USDrug Developmentest. 2015Know BioDurham, NC, US · est. 2015

Know Bio LLC: A life science company dedicated to advancing nitric oxide-based therapies.

Series C · $50.2M125
KBI BiopharmaKBI BiopharmaDurham, NC, USBiopharmaceutical, Manufacturingest. 1996KBI BiopharmaDurham, NC, US · est. 1996

KBI Biopharma, Inc. provides global biopharmaceutical development, manufacturing, and consulting services.

Series A · $9.6M1.7k
KPI TherapeuticsKPI TherapeuticsSeattle, WA, USDrug Developmentest. 2013KPI TherapeuticsSeattle, WA, US · est. 2013

KPI Therapeutics: Accelerating drug development by connecting private investors with healthcare firms since 2013.

Angel · $77.5k30

Brian P McVeigh's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakWillix HalimWillix HalimCEO · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakBo ZhangBo ZhangCo-Founder · DiDiWILL WEI CHENGWILL WEI CHENGBoard Member · DiDi

People Similar to Brian P McVeigh

Don DavidsonDon DavidsonCo-Founder · Creative BioTherapeuticsCory BerklandCory BerklandBoard Member · Orion BioScienceDon HardisonDon HardisonBoard Member · HTG Molecular DiagnosticsJuan EnriquezJuan EnriquezFounder & CEO · BiotechonomyDavid SteinbergDavid SteinbergBoard Member · Rectify Pharmaceuticals